纪宗红,罗善玉,张瑞霞

【摘 要】：代谢性疾病发病率日益升高，其中血脂异常为最重要的一种。他汀类药物被证实对降低血脂有确切疗效，并可降低心血管事件及死亡风险。但不同患者存在遗传差异，可能导致基因型不同，使得服用他汀类药物的疗效与安全性个体差异较大，本综述旨在对溶媒有机阴离子转运蛋白1B1（Solute Carrier Organic Anion Transporter 1B1，SLCO1B）的基因多态性与他汀类药物降脂疗效及临床副作用的研究进展作一阐述，为临床血脂异常的个体化治疗提供一个可能的方向。

【关键词】：SLCO1B1；基因多态性；他汀类

[1] 中国血脂管理指南修订联合专家委员会,李建军,赵水平,等.中国血脂管理指南(2023年)[J].中国循环杂志,2023,38(3):237-271. [2] Brunette C A,Dong O M,Vassy J L,et al.A Cost-Consequence Analysis of Preemptive SLCO1B1 Testing for Statin Myopathy Risk Compared to Usual Care[J].Journal of personalized medicine,2021,11(11). [3] Sivkov A,Chernus N,Gorenkov R,et al.Relationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin,atorvastatin and simvastatin in patients with hyperlipidemia[J].Lipids in Health and Disease,2021,20(1):157. [4] 许娇娇,尹忠鹏,王淑梅,等.血脂异常患者ApoE和SLCO1B1基因多态性与阿托伐他汀调脂治疗后血脂和肝功能的相关性[J].现代药物与临床,2024,39(03):615-620. [5] Ramsey LB,Gong L,Lee SB,Wagner JB,Zhou X,Sangkuhl K,Adams SM,Straka RJ,Empey PE,Boone EC,Klein TE,Niemi M,Gaedigk A.PharmVar GeneFocus:SLCO1B1.Clin Pharmacol Ther.2023 Apr;113(4):782-793. [6] 姚怡,黄朝东,何毅怀等.SLCO1B1基因多态性与2型糖尿病患者血脂关系的研究进展[J].海南医学,2020,31(04):503-507. [7] Brla,Bav,Cas,etal.Evaluation of serum SLCO1B1 levels and genetic variants of SLCO1B1 rs4149056 and rs2306283 in patients with early and exudative age-related macular degeneration-ScienceDirect[J].Gene,2018,676:139-145. [8] Kameyama Y,Yamashita K,Kobayashi K,et al.Functional characterization of SLCO1B1(OATP-C)variants,SLCO1B1*5,SLCO1B1*15 and SLCO1B1*15+C1007G,by using transient expression systems of HeLa and HEK293 cells.[J].Pharmacogenetics and Genomics, 2005,15(7):513-522. [9] 王京伟,李艳,乔斌,等.华中地区汉族人群SLCO1B1与APOE基因多态性分析及临床意义[J].实用医学杂志, 2018, 34(18):3041-3046. [10] Ramsey LB,Gong L,Lee SB,Wagner JB,Zhou X,Sangkuhl K,Adams SM,Straka RJ,Empey PE,Boone EC,Klein TE,Niemi M,Gaedigk A.PharmVar GeneFocus:SLCO1B1.Clin Pharmacol Ther.2023 Apr;113(4):782-793. [11] Pasanen,Marja K.;Neuvonen,Mikko;Neuvonen,Pertti J.;Niemi,Mikko.SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.Pharmacogenetics and Genomics 16(12):p 873-879,December 2006. [12] Shabana MF,Mishriki AA,Issac MS,Bakhoum SW.Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin?A study on a cohort of Egyptian patients with hypercholesterolemia.Mol Diagn Ther.2013 Oct;17(5):299-309. [13] Mo,Q et al.“Association between SLCO1B1 polymorphism distribution frequency and blood lipid level in Chinese adults.”British journal of biomedical science vol.78,1(2021):23-27. [14] The Clinical Pharmacogenetics Implementation Consortium(CPIC)guideline for SLCO1B1,ABCG2,and CYP2C9 and statin- associated musculoskeletal symptoms[J].Clinical Pharmacology&Therapeutics,2022. [15] Kameyama Y,Yamashita K,Kobayashi K,et al.Functional characterization of SLCO1B1(OATP-C)variants,SLCO1B1*5,SLCO1B1*15 and SLCO1B1*15+C1007G,by using transient expression systems of HeLa and HEK293 cells.[J].Pharmacogenetics and Genomics, 2005,15(7):513-522. [16] Birmingham B K,Bujac S R,Elsby R,et al.Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects:a class effect?[J].European Journal of Clinical Pharmacology, 2015,71(3):341-355. [17] Semenov A V,Sichev D A,Kukes V G.effect of genes SLCO1B1 and MDR1 polymorphism on atorvastatin pharmacokinetics and pharmacodynamics in patients with primary hypercholesterolemia:results of pilot pharmacogenetics study[j].racionalna farmakoterapi v kardiologii,2008(2). [18] Yaming,Du,Sizheng,et al.Association of SLCO1B1 polymorphisms and atorvastatin safety and efficacy:A meta-analysis.[J].Current Pharmaceutical Design,2018. [19] Tachibana-Iimori R,Tabara Y,Kusuhara H,et al.Effect of genetic polymorphism of OATP-C(SLCO1B1)on lipid-lowering response to HMG-CoA reductase inhibitors.[J].Drug Metabolism and Pharmacokinetics,2004,19(5):375-380. [20] Sivkov A,Chernus N,Gorenkov R,et al.Relationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin,atorvastatin and simvastatin in patients with hyperlipidemia.[J].Lipids in health and disease,2021,20(1):157. [21] Dai R,Feng J,Wang Y,et al.Association between SLCO1B1 521 T>C and 388 A>G Polymorphisms and Statins Effectiveness:A Meta-Analysis[J].Journal of Japan Atherosclerosis Society,2015. [22] Prado,Y.;Saavedra,N.;Zambrano,T.;Lagos,J.;Rosales,A.;Salazar,L.A.SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals.Int.J.Mol.Sci.2015,16,20609-20619. [23] Shabana M F,Mishriki A A,Issac M S M,et al.Do MDR1 and SLCO1B1 Polymorphisms Influence the Therapeutic Response to Atorvastatin?A Study on a Cohort of Egyptian Patients with Hypercholesterolemia[J].Molecular Diagnosis&Therapy,2013,17(5):299-309. [24] Yan Q K,Peng Y,Cai P,et al.Effect of different doses of rosuvastatin on serum HDL subtypes in patients with hyperlipidemia and coronary heart disease[j].Acta medica mediterranea,2022,38(1):61-65. [25] Yang G P,Yuan H,Tang B,et al.Lack of effect of genetic polymorphisms of SLCO1B1 on the lipid-lowering response to pitavastatin in Chinese patients[J].Acta.pharmacol.sin,2010,31(003):382-386. [26] Birmingham B K,Bujac S R,Elsby R,et al.Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects:a class effect?[J].European Journal of Clinical Pharmacology, 2015,71(3):341-355. [27] Hirota T,Fujita Y,Ieiri I.An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins[J].Expert Opinion on Drug Metabolism&Toxicology,2020,16(9):809-822. [28] Holbrook A,Wright M,Sung M,et al.Statin-associated rhabdomyolysis:is there a dose-response relationship?[J].Canadian Journal of Cardiology,2011,27(2):146-151. [29] Group T S C.SLCO1B1 variants and statin-induced myopathy—a genomewide study[J].New England Journal of Medicine,2008, 2008:789–799. [30] Niemi M,Pasanen M K,Neuvonen P J.SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin [J].Clinical Pharmacology&Therapeutics,2006,80(4):356-366. [31] Tirona R G,Leake B F,Merino G,et al.Polymorphisms in OATP-C identification of multiple allelic variants associated with altered transport activity among european-and african-americans[J].Journal of Biological Chemistry,2001,276(38):35669. [32] Tornio,AleksiVakkilainen,JuhaNeuvonen,MikkoBackman,Janne T.Neuvonen,Pertti J.Niemi,Mikko.SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid[J].Pharmacogenetics and genomics,2015,25(8). [33] Wu X,Gong C,Weinstock J,Cheng J,Hu S,Venners SA,Hsu YH,Wu S,Zha X,Jiang S,Li Y,Pan F,Xu X.Associations of the SLCO1B1 Polymorphisms With Hepatic Function,Baseline Lipid Levels,and Lipid-lowering Response to Simvastatin in Patients With Hyperlipidemia.Clin Appl Thromb Hemost.2018 Dec;24(9_suppl):240S-247S. [34] Hu M,Tomlinson B.Effects of statin treatments and polymorphisms in UGT1A1 and SLCO1B1 on serum bilirubin levels in Chinese patients with hypercholesterolaemia.Atherosclerosis.2012 Aug;223(2):427-32.

点击下载PDF